Published in:
01-03-2021 | Metronidazole | Brief Report
The vaginal microbiota in the course of bacterial vaginosis treatment
Authors:
Romy D. Zwittink, Ellen H. A. van den Munckhof, Maurine A. Leverstein-van Hall, Kim Boers, Anco Molijn, Cornelis W. Knetsch, Ed J. Kuijper
Published in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Issue 3/2021
Login to get access
Abstract
Bacterial vaginosis (BV) is perceived as a condition of disrupted vaginal microbiota, but remains of unknown aetiology. In this study, vaginal microbiota composition was determined in twenty-one women with BV, before and after treatment with metronidazole or clindamycin. Microbiota composition varied greatly between women and defining a (un)healthy vaginal microbiota state remains elusive, challenging BV diagnosis and treatment. While relative abundance of Lactobacillus increased after antibiotic treatment in two-third of women, its abundance was not associated with treatment outcome. Instead, remaining complaints of abnormal vaginal discharge were more common after metronidazole treatment and associated with increased relative abundance of Ureaplasma.